Figure 3.
Longitudinal monitoring of FVIII-binding antibodies and FVIII inhibitors in the 2 patients in subgroup 3. (A-B) Results of the analysis of FVIII-binding antibodies (IgG1, IgG2, IgG3, IgG4, IgA, and IgM, as indicated) and FVIII inhibitors (BU/mL) for the 2 patients in subgroup 3, patient 15 (A) and patient 16 (B), who developed FVIII-binding IgG1 antibodies and transient low-titer FVIII inhibitors. The red dotted lines represent the limit for positive evaluation of FVIII inhibitors (0.6 BU/mL). (C-D) Apparent affinity constants of FVIII-binding IgG1 antibodies (mean KA) and FVIII inhibitors (BU/mL) in patient 15 (C) and patient 16 (D). Data for apparent affinity constants include the 95% CIs for up to 2 IgG1 affinity clusters (open blue bars, IgG1 population 1; closed blue bars, IgG1 population 2). The red dotted lines represent the limit for positive evaluation of FVIII inhibitors (0.6 BU/mL).

Longitudinal monitoring of FVIII-binding antibodies and FVIII inhibitors in the 2 patients in subgroup 3. (A-B) Results of the analysis of FVIII-binding antibodies (IgG1, IgG2, IgG3, IgG4, IgA, and IgM, as indicated) and FVIII inhibitors (BU/mL) for the 2 patients in subgroup 3, patient 15 (A) and patient 16 (B), who developed FVIII-binding IgG1 antibodies and transient low-titer FVIII inhibitors. The red dotted lines represent the limit for positive evaluation of FVIII inhibitors (0.6 BU/mL). (C-D) Apparent affinity constants of FVIII-binding IgG1 antibodies (mean KA) and FVIII inhibitors (BU/mL) in patient 15 (C) and patient 16 (D). Data for apparent affinity constants include the 95% CIs for up to 2 IgG1 affinity clusters (open blue bars, IgG1 population 1; closed blue bars, IgG1 population 2). The red dotted lines represent the limit for positive evaluation of FVIII inhibitors (0.6 BU/mL).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal